Interní Med. 2003; 5(3): 102-108
Published: December 31, 2003 Show citation
Hyperliproteinémie provázející metabolický syndrom je charakterizována třemi fenomény: zvýšenou triglyceridémií, sníženým HDL cholesterolem a přítomností tzv. malých denzních oxidovaných LDL částic. Přestože celkový cholesterol není zvýšen, jde o výrazně aterogenní kombinaci. Nízká hladina HDL cholesterolu a hypertriglyceridémie přitom patří k tzv. jádru metabolického syndromu a má velmi pevnou vazbu na inzulinorezistenci. V léčbě rizikových nemocných vyjádřenými více složkami metabolického syndromu musí být využity všechny nefarmakologické i farmakologické postupy k normalizaci hladiny triglyceridů, HDL cholesterolu i LDL cholesterolu.
Dyslipidemia of metabolic syndrome is characterised by 3 phenomena: high triacylglycerol level, low level of HDL-cholesterol and presence of small dense oxidized LDL-particles. Although the level of total choplesterol is not increased, this dyslipidemia is very atrherogenic. Low level of HDL-cholesterol and hypertriacylglycerolemia is a part of so called core of metabolic syndrom with a strong relation to insulin resistance. It is necessary to use all non-pharmacological and pharmacological approaches to normalise the level of triacylglycerols, HDL-cholesterol and LDL-cholesterol in these high risk patients.
Download citation Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed... Go to original source...
Go to original source...  Go to PubMed...
Go to PubMed...